Posterior Uveitis Associated with Cemiplimab.
Sign Up to like & getrecommendations! Published in 2021 at "Ocular immunology and inflammation"
DOI: 10.1080/09273948.2021.1872649
Abstract: PURPOSE The immune checkpoint inhibitors (ICPIs) comprise a class of oncologic immunotherapies. The most recent US Food and Drug Administration-approved ICPI is cemiplimab (Libtayo®). Cemiplimab, like the other ICPIs, blocks checkpoint receptors in order to… read more here.
Keywords: posterior uveitis; treatment; cemiplimab; associated cemiplimab ... See more keywords
Cemiplimab for locally advanced and metastatic basal cell carcinoma
Sign Up to like & getrecommendations! Published in 2022 at "Expert Review of Anticancer Therapy"
DOI: 10.1080/14737140.2022.2043748
Abstract: ABSTRACT Introduction Locally advanced basal cell carcinoma (laBCC) represents approximatively 1% of all BCCs. Metastatic BCC (mBCC) is even more rare. Most cases are observed in immunocompromised patients, particularly solid organ transplant recipients (OTRs). When… read more here.
Keywords: labcc mbcc; therapy; cemiplimab; cell ... See more keywords
Immunotherapy (Cemiplimab)-Induced Bullous Pemphigoid: A Possible Pitfall in 18F-FDG PET/CT.
Sign Up to like & getrecommendations! Published in 2021 at "Clinical nuclear medicine"
DOI: 10.1097/rlu.0000000000003894
Abstract: ABSTRACT A 78-year-old man with multiple squamous cell carcinomas of the skin underwent 18F-FDG-PET/CT for restaging after 4 cycles of cemiplimab. The scan showed new disseminated FDG-avid skin lesions. Dermatologic examination and biopsy revealed bullous… read more here.
Keywords: bullous pemphigoid; 18f fdg; cemiplimab; fdg pet ... See more keywords
Cemiplimab in advanced cutaneous squamous cell carcinoma.
Sign Up to like & getrecommendations! Published in 2021 at "Dermatologic therapy"
DOI: 10.1111/dth.15184
Abstract: Cemiplimab, a high-affinity, highly potent human monoclonal antibody that binds to the programmed death-1 (PD-1)/programmed death ligand-1 (PD-L1) receptor, is the only drug to attain Food and Drug Administration (FDA) approval and marketing authorization from… read more here.
Keywords: squamous cell; cell carcinoma; cutaneous squamous; cemiplimab ... See more keywords
The efficacy and safety of cemiplimab in locally advanced or metastatic cutaneous squamous cell carcinoma: A comparative analysis of retrospective studies versus prospective studies
Sign Up to like & getrecommendations! Published in 2022 at "Dermatologic Therapy"
DOI: 10.1111/dth.15715
Abstract: Cemiplimab has been widely recommended by international guidelines to treat patients with locally advanced or metastatic cutaneous squamous cell carcinoma (CSCC). In this study, we conducted a comparative analysis to integrate the efficacy and safety… read more here.
Keywords: locally advanced; metastatic cutaneous; prospective studies; cemiplimab ... See more keywords
First-In-Human Study of Cemiplimab Alone or In Combination with Radiotherapy and/or Low-dose Cyclophosphamide in Patients with Advanced Malignancies
Sign Up to like & getrecommendations! Published in 2019 at "Clinical Cancer Research"
DOI: 10.1158/1078-0432.ccr-19-2609
Abstract: Purpose: This first-in-human study assessed the safety, tolerability, dose-limiting toxicities (DLT), antitumor activity, and pharmacokinetics of cemiplimab, a monoclonal anti-programmed cell death-1 (PD-1), as monotherapy and in combination with hypofractionated radiotherapy (hfRT) and/or cyclophosphamide (CPA)… read more here.
Keywords: patients advanced; human study; first human; combination ... See more keywords
Abstract CT114: INO-5401 and INO-9012 delivered by electroporation (EP) in combination with cemiplimab (REGN2810) in newly-diagnosed glioblastoma (GBM) (NCT03491683)
Sign Up to like & getrecommendations! Published in 2019 at "Cancer Research"
DOI: 10.1158/1538-7445.sabcs18-ct114
Abstract: Despite advances in therapy, glioblastoma (GBM) remains one of the most deadly cancers, with five-year survival under 5%. Newer immunotherapies hold promise in the treatment of GBM, and T cell-enabling therapies may improve progression-free and… read more here.
Keywords: ino 9012; ino 5401; cemiplimab; ino ... See more keywords
Brief overview: cemiplimab for the treatment of advanced basal cell carcinoma: PD-1 strikes again
Sign Up to like & getrecommendations! Published in 2022 at "Therapeutic Advances in Medical Oncology"
DOI: 10.1177/17588359211066147
Abstract: Basal cell carcinoma (BCC) is the most common malignancy worldwide. Fortunately, most tumors are localized and easily amenable to surgical resection or locally destructive treatments. However, a subset of BCCs can become locally advanced or… read more here.
Keywords: cell carcinoma; cemiplimab; basal cell;
PD-1 N58-Glycosylation-Dependent Binding of Monoclonal Antibody Cemiplimab for Immune Checkpoint Therapy
Sign Up to like & getrecommendations! Published in 2022 at "Frontiers in Immunology"
DOI: 10.3389/fimmu.2022.826045
Abstract: Immune checkpoint therapy (ICT) with a monoclonal antibody (MAb) against programmed cell death protein 1 (PD-1) is a powerful clinical treatment for tumors. Cemiplimab is a human IgG4 antibody approved in 2018 and is the… read more here.
Keywords: immune checkpoint; n58 glycosylation; checkpoint therapy; glycosylation ... See more keywords
Real-Life Study of the Benefit of Concomitant Radiotherapy with Cemiplimab in Advanced Cutaneous Squamous Cell Carcinoma (cSCC): A Retrospective Cohort Study
Sign Up to like & getrecommendations! Published in 2023 at "Cancers"
DOI: 10.3390/cancers15020495
Abstract: Simple Summary Cemiplimab is used in the treatment of advanced cutaneous squamous cell carcinoma. Synergistic antitumoral response by concurrent radiotherapy and immunotherapy seems promising. We collected data from patients who were administered cemiplimab in Caen… read more here.
Keywords: advanced cutaneous; radiotherapy; group; cemiplimab ... See more keywords
Promising Immune Treatment of Advanced Cutaneous Squamous Cell Carcinoma with Cemiplimab—Real-World Experience in the Global SARS-CoV-2 Pandemic
Sign Up to like & getrecommendations! Published in 2022 at "Current Oncology"
DOI: 10.3390/curroncol29100616
Abstract: Cutaneous squamous cell carcinoma (cSCC) is the second most frequent non-melanoma skin cancer. The standard curative treatment is surgical resection, but the treatment of locally advanced and metastatic disease apart from radiotherapy is currently based… read more here.
Keywords: oncology; cell carcinoma; cutaneous squamous; squamous cell ... See more keywords